Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Allogeneic CAR-T Cells: More than Ease of Access?
Graham C, Jozwik A, Pepper A, Benjamin R. Graham C, et al. Among authors: jozwik a. Cells. 2018 Oct 1;7(10):155. doi: 10.3390/cells7100155. Cells. 2018. PMID: 30275435 Free PMC article. Review.
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.
Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Boissel N, Maus MV, Frigault MJ, Baruchel A, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W; UCART19 Group. Benjamin R, et al. Among authors: jozwik a. Lancet. 2020 Dec 12;396(10266):1885-1894. doi: 10.1016/S0140-6736(20)32334-5. Lancet. 2020. PMID: 33308471 Clinical Trial.
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group. Benjamin R, et al. Among authors: jozwik a. Lancet Haematol. 2022 Nov;9(11):e833-e843. doi: 10.1016/S2352-3026(22)00245-9. Epub 2022 Oct 10. Lancet Haematol. 2022. PMID: 36228643 Clinical Trial.
Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma.
Graham CE, Jozwik A, Quartey-Papafio R, Ioannou N, Metelo AM, Scala C, Dickson G, Stewart O, Almena-Carrasco M, Peranzoni E, Ramsay AG, Patten PEM, Pertel T, Farzaneh F, Dupouy S, Pepper A, Benjamin R. Graham CE, et al. Among authors: jozwik a. Leukemia. 2021 Dec;35(12):3581-3584. doi: 10.1038/s41375-021-01324-z. Epub 2021 Jun 18. Leukemia. 2021. PMID: 34145373 Free PMC article. No abstract available.
Emerging Cellular Therapies: T Cells and Beyond.
Todryk S, Jozwik A, de Havilland J, Hester J. Todryk S, et al. Among authors: jozwik a. Cells. 2019 Mar 26;8(3):284. doi: 10.3390/cells8030284. Cells. 2019. PMID: 30917514 Free PMC article.
Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M, Domagala P, Miszewska-Szyszkowska D, Sitarek E, Jozwik A, Kwiatkowski A, Durlik M. Deborska-Materkowska D, et al. Among authors: jozwik a. BMC Infect Dis. 2018 Apr 16;18(1):179. doi: 10.1186/s12879-018-3075-z. BMC Infect Dis. 2018. PMID: 29661141 Free PMC article.
126 results